{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:31:10Z","timestamp":1780479070943,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-10998-9","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:20:27Z","timestamp":1722975627000},"page":"1057-1066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparing embolic particles for prostatic artery embolization to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3044-8474","authenticated-orcid":false,"given":"Tiago","family":"Bilhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Vasco Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Ak\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luisa","family":"Papoila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"10998_CR1","doi-asserted-by":"crossref","unstructured":"Sandhu JS, Bixler BR, Dahm P et al (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment. J Urol 211:11\u201319","DOI":"10.1097\/JU.0000000000003698"},{"key":"10998_CR2","unstructured":"Gravas S, Cornu JN, Gacci M et al (2000) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Management-of-Non-Neurogenic-Male-LUTS-2021.pdf. Access 24 Nov. 2023"},{"key":"10998_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jvir.2019.02.013","volume":"30","author":"JP McWilliams","year":"2019","unstructured":"McWilliams JP, Bilhim TA, Carnevale FC et al (2019) Society of Interventional Radiology multisociety consensus position statement on prostatic artery embolization for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia: from the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Soci\u00e9t\u00e9 Fran\u00e7aise de Radiologie, and the British Society of Interventional Radiology. Endorsed by the Asia Pacific Society of Cardiovascular and Interventional Radiology, Canadian Association for Interventional Radiology, Chinese College of Interventionalists, Interventional Radiology Society of Australasia, Japanese Society of Interventional Radiology, and Korean Society of Interventional Radiology. J Vasc Interv Radiol 30:627\u2013637","journal-title":"J Vasc Interv Radiol"},{"key":"10998_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00270-019-02379-3","volume":"43","author":"FH Cornelis","year":"2020","unstructured":"Cornelis FH, Bilhim T, Hacking N, Sapoval M, Tapping CR, Carnevale FC (2020) CIRSE standards of practice on prostatic artery embolisation. Cardiovasc Interv Radiol 43:176\u2013185","journal-title":"Cardiovasc Interv Radiol"},{"key":"10998_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00270-023-03617-5","volume":"47","author":"T Bilhim","year":"2024","unstructured":"Bilhim T, McWilliams JP, Bagla S (2024) Updated American Urological Association Guidelines for the Management of Benign Prostatic Hyperplasia: prostatic artery embolization made it into the guidelines! Cardiovasc Intervent Radiol 47:150\u2013153","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10998_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00270-015-1202-4","volume":"39","author":"FC Carnevale","year":"2016","unstructured":"Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M (2016) Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 39:44\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10998_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100672","volume":"31","author":"M Sapoval","year":"2023","unstructured":"Sapoval M, Thiounn N, Descazeaud A et al (2023) Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur 31:100672","journal-title":"Lancet Reg Health Eur"},{"key":"10998_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jvir.2010.09.030","volume":"22","author":"JM Pisco","year":"2011","unstructured":"Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22:11\u201319","journal-title":"J Vasc Interv Radiol"},{"key":"10998_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14249","volume":"122","author":"AF Ray","year":"2018","unstructured":"Ray AF, Powell J, Speakman MJ et al (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 122:270\u2013282","journal-title":"BJU Int"},{"key":"10998_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1148\/radiol.13122803","volume":"270","author":"YA Gao","year":"2014","unstructured":"Gao YA, Huang Y, Zhang R et al (2014) Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate-a prospective, randomized, and controlled clinical trial. Radiology 270:920\u2013928","journal-title":"Radiology"},{"key":"10998_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.02.008","volume":"80","author":"D Abt","year":"2021","unstructured":"Abt D, Mullhaupt G, Hechelhammer L et al (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol 80:34\u201342","journal-title":"Eur Urol"},{"key":"10998_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jvir.2019.12.810","volume":"31","author":"I Insausti","year":"2020","unstructured":"Insausti I, Saez de Ocariz A, Galbete A et al (2020) Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 31:882\u2013890","journal-title":"J Vasc Interv Radiol"},{"key":"10998_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2019.11.010","volume":"77","author":"JM Pisco","year":"2020","unstructured":"Pisco JM, Bilhim T, Costa NV et al (2020) Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol 77:354\u2013362","journal-title":"Eur Urol"},{"key":"10998_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00270-022-03199-8","volume":"45","author":"T Bilhim","year":"2022","unstructured":"Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E (2022) Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol 45:1324\u20131336","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10998_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1148\/radiol.2016152292","volume":"281","author":"T Bilhim","year":"2016","unstructured":"Bilhim T, Pisco J, Pereira JA et al (2016) Predictors of clinical outcome after prostate artery embolization with spherical and nonspherical polyvinyl alcohol particles in patients with benign prostatic hyperplasia. Radiology 281:289\u2013300","journal-title":"Radiology"},{"key":"10998_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8732351","volume":"2017","author":"JH Hwang","year":"2017","unstructured":"Hwang JH, Park SW, Chang IS et al (2017) Comparison of nonspherical polyvinyl alcohol particles and microspheres for prostatic arterial embolization in patients with benign prostatic hyperplasia. Biomed Res Int 2017:8732351","journal-title":"Biomed Res Int"},{"key":"10998_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL (2017) CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol 40:1141\u20131146","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10998_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10439-022-02965-6","volume":"50","author":"R Talaie","year":"2022","unstructured":"Talaie R, Torkian P, Amili O et al (2022) Particle distribution in embolotherapy, how do they get there? A critical review of the factors affecting arterial distribution of embolic particles. Ann Biomed Eng 50:885\u2013897","journal-title":"Ann Biomed Eng"},{"key":"10998_CR19","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1007\/s00330-020-07663-2","volume":"31","author":"P Xiang","year":"2021","unstructured":"Xiang P, Guan D, Du Z et al (2021) Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol 31:4929\u20134946","journal-title":"Eur Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10998-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:54:23Z","timestamp":1738277663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10998-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["10998"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10998-9","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is T.B.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"T.B. is a paid consultant for Merit Medical, has received speaker fees for Philips Medical, Cook Medical, Terumo, and is a stockholder for EmbolX. N.V.C. is a paid consultant for Merit Medical. The remaining authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Two of the authors (M.A. and A.L.P.) have significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No overlap\u2014100% original work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}